Ihle, NT and Lemos, R and Schwartz, D and Oh, J and Halter, RJ and Wipf, P and Kirkpatrick, L and Powis, G
(2009)
Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Molecular Cancer Therapeutics, 8 (1).
94 - 100.
ISSN 1535-7163
![[img]](http://d-scholarship-dev.library.pitt.edu/style/images/fileicons/text_plain.png) |
Plain Text (licence)
Available under License : See the attached license file.
Download (1kB)
|
Abstract
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is an important component of the insulin signaling in normal tissues leading to glucose uptake and homeostasis and for cell survival signaling in cancer cells. Hyperglycemia is an on-target side effect of many inhibitors of PI3K/Akt signaling including the specific PI3K inhibitor PX-866. The peroxisome proliferator-activated receptor γ agonist pioglitazone, used to treat type 2 diabetes, prevents a decrease in glucose tolerance caused by acute administration of PX-866. Our studies have shown that pioglitazone does not inhibit the antitumor activity of PX-866 in A-549 non-small cell lung cancer and HT-29 colon cancer xenografts. In vitro studies also showed that pioglitazone increases 2-[1-14C]deoxy-D-glucose uptake in L-6 muscle cells and prevents inhibition of 2-deoxyglucose uptake by PX-866. Neither pioglitazone nor PX-866 had an effect on 2-deoxyglucose uptake in A-549 lung cancer cells. In vivo imaging studies using [18F]2-deoxyglucose (FDG) positron emission tomography showed that pioglitazone increases FDG accumulation by normal tissue but does not significantly alter FDG uptake by A-549 xenografts. Thus, peroxisome proliferator-activated receptor γ agonists may be useful in overcoming the increase in blood glucose caused by inhibitors of PI3K signaling by preventing the inhibition of normal tissue insulin-mediated glucose uptake without affecting antitumor activity. Copyright © 2009 American Association for Cancer Research.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID ![](/images/orcid_id_24x24.png) |
---|
Ihle, NT | | | | Lemos, R | | | | Schwartz, D | | | | Oh, J | | | | Halter, RJ | | | | Wipf, P | pwipf@pitt.edu | PWIPF | | Kirkpatrick, L | | | | Powis, G | | | |
|
Date: |
1 January 2009 |
Date Type: |
Publication |
Journal or Publication Title: |
Molecular Cancer Therapeutics |
Volume: |
8 |
Number: |
1 |
Page Range: |
94 - 100 |
DOI or Unique Handle: |
10.1158/1535-7163.mct-08-0714 |
Schools and Programs: |
Dietrich School of Arts and Sciences > Chemistry |
Refereed: |
Yes |
ISSN: |
1535-7163 |
MeSH Headings: |
Animals; Antineoplastic Agents--pharmacology; Cell Line, Tumor; Disease Progression; Glucose--metabolism; Glucose Transport Proteins, Facilitative--metabolism; Glucose-6-Phosphate--analogs & derivatives; Glucose-6-Phosphate--metabolism; Gonanes--pharmacology; Humans; Hyperglycemia--enzymology; Hyperglycemia--prevention & control; Mice; Neoplasms--drug therapy; Neoplasms--pathology; PPAR gamma--agonists; PPAR gamma--metabolism; Phosphatidylinositol 3-Kinases--metabolism; Signal Transduction--drug effects; Thiazolidinediones--pharmacology; Thiazolidinediones--therapeutic use; Xenograft Model Antitumor Assays |
Other ID: |
NLM NIHMS87811, NLM PMC2633941 |
PubMed Central ID: |
PMC2633941 |
PubMed ID: |
19139117 |
Date Deposited: |
03 Jul 2013 14:49 |
Last Modified: |
12 Jun 2021 22:56 |
URI: |
http://d-scholarship-dev.library.pitt.edu/id/eprint/19216 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
![View Item View Item](/style/images/action_view.png) |
View Item |